BPCO对肝癌细胞的抗瘤作用
Shan-Bin Li1,2, Tong-Shi-Yao Zhao1, Zhen Ye3
1College of Biotechnology, Guilin Medical University, Guilin541199, China.
Journal of Asian natural products research
|February 22, 2025
概括
这项研究合成了一种新型的 esculetin 衍生物,BPCO,它有效地抑制肝细胞癌细胞增殖并诱导细胞亡. 作为肝癌治疗的潜在新型抗瘤剂,BPCO显示出前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 埃斯库莱是一种天然氨酸,具有抗癌性质.
- 肝细胞癌 (HCC) 仍然是一个重大的全球健康挑战.
- 需要新的治疗药物来对抗HCC的进展.
研究的目的:
- 为了合成和评估一种新的 esculetin 衍生物,6,7-bis(Pentyloxy)-2H-Chromen-2-One (BPCO).
- 研究BPCO对肝细胞癌 (HepG2) 细胞增殖,迁移,细胞亡和细胞周期的影响.
- 探索BPCO抗瘤活性背后的分子机制.
主要方法:
- 乙化用于合成BPCO衍生物.
- 用BPCO对待HepG2细胞,以评估其对增殖和迁移的影响.
- 流细胞计被用来分析细胞周期分布和细胞亡.
- 进行了西部涂抹,以检查与亡相关的蛋白质 (Bcl-2,Bcl-XL,Bax,Bak) 的表达.
主要成果:
- 在剂量和时间上,BPCO显著抑制了HepG2细胞的增殖和迁移.
- BPCO诱导了亡,并在HepG2细胞的G1阶段导致细胞周期停止.
- 治疗BPCO导致抗亡蛋白 (Bcl-2,Bcl-XL) 的下调和亲亡蛋白 (Bax,Bak) 的上调.
结论:
- 合成的 esculetin 衍生品,BPCO,对肝细胞癌细胞表现出强大的抗癌作用.
- 通过调节关键的亡蛋白质,BPCO有效地抑制癌细胞的增殖,并诱导亡.
- 作为HCC的抗瘤剂,BPCO代表了进一步开发的有希望的候选人.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K